Recent Advances in Drugs for Mitochondrial Diseases

USD 950

* Required Fields

USD 950

PAY BY INVOICE

Be the first to review this product

Mitochrondrial diseases arise when there is a malfunctioning mitochondria. These diseases are sometimes cause by genetic anomalies and can also be acquired hereditarily. While some mitocondrial disorders affect only a single organ such as Leber hereditary optic neuropathy (LHON), there are others that can result in problems across multiple organs. However, extensive research is taking place for treating these rare disease, with multiple starts up receiving funding for their efforts in gene therapy, cellular therapy, and small molecule therapeutics.

The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.

The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Mitochondrial disorder, mitochondria, small molecule therapeutics

Table of Contents

Recent Advances in Drugs for Mitochondrial DiseasesNew Approaches in Drug Discovery and DevelopmentInduced Pluripotent Stem Cells as Effective Therapies for Mitochondrial DiseaseRectifying Mitochondrial Defects by Modulating Enzyme Nicotinamide Adenine Dinucleotide LevelsSmall Molecule Therapeutics for Inherited Mitochondrial DiseasesModulating Mitochondria Function by Increasing Energy ExpenditureMitochondria-based Therapeutics for Age-related DiseasesBreakthrough Drug Reversing Mitochondrial Dysfunction for Parkinson’s DiseaseRedox Drugs for Rare Inherited Mitochondrial Disease Mitochondrial Disease Drug Discovery – Technology Focus and TrendsMitochondrial Target Molecules Emerging as Novel Therapeutics for Diseases with Unmet Need for TherapeuticsThree Start Ups to Note Industry InteractionsIndustry Interactions




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 08-Dec-17

Region : Global

Release Date : 08-Dec-17

Region : Global

Release Date : 01-Dec-17

Region : Global

Release Date : 29-Nov-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.